CalciMedica (CALC)
NASDAQ:CALC
CALC Stock Chart & Stats
$0.62
<$0.01(0.05%)
At close: 4:00 PM EST
$0.62
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$9.07M
Enterprise Value$7.25M
Total Cash (Recent Filing)$13.02M
Total Debt (Recent Filing)$9.70M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
May 18, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding15,743,916
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-54.43
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.45K
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$10.00Price Target Upside1512.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalCARPO study demonstrated a statistically significant dose response and meaningful improvement in time to solid food tolerance in highly inflamed patients, supporting further development and a potentially differentiated clinical profile.
Lead Program Value DriverAnalyst's view positions the Acute Pancreatitis program as the primary value driver following strategic refocus away from the Acute Kidney Injury program, concentrating resources on the most promising commercial opportunity.
Pipeline DiversificationA preclinical candidate for pulmonary arterial hypertension advancing toward an investigational new drug filing provides pipeline diversification beyond the lead program and could create additional upside if it enters clinical development.
Bears Say
Program Spillover RiskUnclear whether the safety concern in the kidney injury study will affect the design or prospects of the Acute Pancreatitis and pediatric programs, creating potential regulatory and developmental risk across the pipeline.
Safety Signal UncertaintyA safety issue observed more frequently in the treated group, even if not clearly linked to the drug, raises unresolved safety questions that complicate risk assessment for the program.
Trial Halt Removes CatalystAn independent safety committee's recommendation to stop the KOURAGE trial removed a key anticipated catalyst and increased uncertainty around the program's regulatory and development path.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $9.07M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is May 18, 2026 which is in 53 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Mar 03, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.268.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.28.
How many shares outstanding does CalciMedica have?
CalciMedica has 15,743,916 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went up 14.398%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
CALC Stock 12 Month Forecast
Average Price Target
$10.00
▲(1512.90% Upside)
Technical Analysis
Ownership Overview
31.96% Insiders
2.78% Mutual Funds
17.79% Other Institutional Investors
45.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---